Mer­ck and As­traZeneca get Lyn­parza OK in Chi­na for new in­di­ca­tion; BAR­DA ex­er­cis­es first op­tion with Mar­i­nus

As­traZeneca and Mer­ck’s Lyn­parza is ap­proved in Chi­na for yet an­oth­er in­di­ca­tion.

Chi­nese reg­u­la­tors ap­proved the block­buster can­cer drug and PARP in­hibitor as a first …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER